NASDAQ · SCNI
Healthcare · Biotechnology
$1.56
Down-$0.06 (-3.70%)
Updated Sep 20, 2026, 10:36 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SCNI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning SCNI.
SCNI research
Company profile and research snapshot.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 15, 2026
Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences (NASDAQ:JUNS) stock
Benzinga · Sep 15, 2026
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares increased by
ChartMill · Sep 14, 2026
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Benzinga · Sep 14, 2026
U.S. stocks fell Monday, led by a 2% tech decline. Nvidia may invest $10B in Anthropic; oil jumped 4.2%, while European markets mostly slipped.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SCNI.
No results
No recent SID articles mention SCNI.
